Abbott Laboratories Q2 Earnings: Revenue And Profit Beat Estimates, Nudges Up Annual Profit Guidance On Strong Medical Devices Growth
Abbott Laboratories Q2 Earnings: Revenue And Profit Beat Estimates, Nudges Up Annual Profit Guidance On Strong Medical Devices Growth
On Thursday, Abbott Laboratories (NYSE:ABT) reported second-quarter sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 billion.
周四，雅培实验室(NYSE:ABT)报告了2024年第二季度销售额为103.8亿美元，增长4%，几乎符合预期的103.7亿美元。
Organic sales growth for the underlying base business was 9.3%, led by double-digit growth in Medical Devices.
基础业务的有机销售增长率为9.3%，其中医疗器械业务的销售增长率在两位数以上。
Abbott's adjusted diluted earnings per share was $1.14, beating the analyst estimates of $1.10.
雅培的调整后稀释每股收益为1.14美元，超出分析师的预期1.10美元。
Medical Devices sales increased 10.2% to $4.73 billion and 12.1% organically in the second quarter, including double-digit organic growth in the U.S. and internationally. Sales growth was led by double-digit growth in Diabetes Care, Electrophysiology, and Structural Heart.
第二季度医疗器械销售额为47.3亿美元，增长10.2%，有机增长12.1%，包括美国和国际双位数有机增长。增长主要来自糖尿病护理、心脏电生理学和结构性心脏的双位数增长。
Year-over-year declines in COVID-19 testing-related sales negatively impacted diagnostics sales growth in the second quarter. Sales reached $2.19 billion, down 5.3% (-1.5% organically).
第二季度COVID-19测试相关销售同比下降，对诊断业务销售增长产生了负面影响。销售额达到21.9亿美元，同比下降5.3%（有机下降1.5%）。
Worldwide COVID-19 testing sales were $102 million in the second quarter of 2024 compared to $263 million a year ago.
2024年第二季度全球COVID-19测试销售额为10200万美元，相比之下去年同期为26300万美元。
Nutrition sales increased 3.5% to $2.15 billion (+7.5% organically).
营养品销售额增长了3.5%至21.5亿美元（有机增长7.5%）。
In June, Abbott announced FDA approval for two new over-the-counter continuous glucose monitoring systems: Lingo and Libre Rio. These systems are based on Abbott's FreeStyle Libre continuous glucose monitoring technology.
6月，雅培宣布FDA批准了两个新的非处方连续血糖监测系统：Lingo和Libre Rio。这些系统基于雅培的FreeStyle Libre连续血糖监测技术。
During the first half of 2024, Abbott announced ten new growth opportunities from the company's pipeline.
2024年上半年，雅培宣布了来自公司管线的10个新的增长机会。
Guidance: Abbott projects full-year 2024 GAAP EPS of $3.30-$3.40 versus prior guidance of $3.25-$3.40, primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses.
展望：雅培预计2024年全年GAAP每股收益为3.30-3.40美元，比先前的指引3.25-3.40美元略高，主要与无形资产摊销、重组和成本削减计划以及其他净开支有关。
The company forecasts adjusted EPS of $4.61-$4.71 versus the prior guidance of $4.55-$4.70 and consensus of $4.63.
该公司预计调整后每股收益为4.61-4.71美元，而先前的指引为4.55-4.70美元，预期为4.63美元。
Price Action: At the last check on Thursday, ABT shares were down 2.52% at $102.04.
股价表现：周四最后一次查看时，雅培(ABT)的股价下跌2.52%，至102.04美元。
- Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits.
- Similac奶粉制造商Abbott和Reckitt面临数百起婴儿配方奶粉诉讼。
Photo via Shutterstock
图片来自shutterstock。